CytoDyn Inc.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Revenue | $0 | $266.0K | $0 |
| Cost of Revenue | — | $53.0K | — |
| Gross Profit | — | $213.0K | — |
| Gross Margin | — | 80.1% | — |
| Operating Expenses | |||
| Research & Development | $2.6M | $27.0M | $53.4M |
| SG&A Expense | $17.1M | $44.3M | $34.3M |
| Operating Income | $-40.6M | $-145.4M | $-104.6M |
| Operating Margin | — | -54,663.2% | — |
| Interest Expense | — | — | — |
| Pretax Income | $-79.8M | $-210.8M | $-176.5M |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-79.8M | $-210.8M | $-176.5M |
| Net Margin | — | -79,255.6% | — |
| EPS (Basic) | $-0.10 | $-0.31 | $-0.30 |
| EPS (Diluted) | $-0.10 | $-0.31 | $-0.30 |
| Shares Outstanding (Basic) | 836.5M | 676.9M | 587.6M |
| Shares Outstanding (Diluted) | 836.5M | 676.9M | 587.6M |
| Dividends Per Share | — | — | — |